Anticancer research · 2025
Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive Bladder Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Mingxing, Lu Jianming, Yu Wenshi, Li Yaxian, Wu Yonglu, Yao Yuhui, Tian Huizhen, Huang Liangliang, Zhang L E, Deng Junhong
Аннотация
BACKGROUND/AIM: Muscle-invasive bladder cancer (MIBC) represents a significant clinical challenge due to its aggressive nature. Identifying reliable biomarkers to predict prognosis is critical for improving patient outcomes. Nucleoporin 188 (NUP188), a component of nuclear pore complexes, has emerged as a potential candidate, yet its role in MIBC remains underexplored.
MATERIALS AND METHODS: This study analyzed NUP188 expression across multicenter MIBC cohorts from TCGA, GSE48075, and GSE169455, as well as the immunotherapy cohorts, using Kaplan-Meier survival analysis and Cox regression to assess prognostic significance. In vitro assays in 5637 and UM-UC-3 cell lines evaluated the effects of NUP188 knockdown on proliferation and migration. Pathway enrichment and Gene Set Variation Analysis (GSVA) were employed to investigate mechanistic associations.
RESULTS: Elevated NUP188 expression was consistently associated with poor overall survival, progression-free interval, and disease-specific survival across MIBC cohorts, establishing it as an independent adverse prognostic factor. In the immunotherapy cohorts, high NUP188 levels correlated with reduced survival and immunotherapy non-responsiveness. In vitro, NUP188 silencing significantly suppressed proliferation and migration of MIBC cell lines. In addition, NUP188 was linked to metabolic reprogramming, particularly lipid metabolism, and exhibited distinct mutational profiles.
CONCLUSION: NUP188 emerges as a novel biomarker predictive of poor prognosis in MIBC. Its influence on cellular proliferation, migration, and metabolic pathways underscores its potential as a therapeutic target.
MATERIALS AND METHODS: This study analyzed NUP188 expression across multicenter MIBC cohorts from TCGA, GSE48075, and GSE169455, as well as the immunotherapy cohorts, using Kaplan-Meier survival analysis and Cox regression to assess prognostic significance. In vitro assays in 5637 and UM-UC-3 cell lines evaluated the effects of NUP188 knockdown on proliferation and migration. Pathway enrichment and Gene Set Variation Analysis (GSVA) were employed to investigate mechanistic associations.
RESULTS: Elevated NUP188 expression was consistently associated with poor overall survival, progression-free interval, and disease-specific survival across MIBC cohorts, establishing it as an independent adverse prognostic factor. In the immunotherapy cohorts, high NUP188 levels correlated with reduced survival and immunotherapy non-responsiveness. In vitro, NUP188 silencing significantly suppressed proliferation and migration of MIBC cell lines. In addition, NUP188 was linked to metabolic reprogramming, particularly lipid metabolism, and exhibited distinct mutational profiles.
CONCLUSION: NUP188 emerges as a novel biomarker predictive of poor prognosis in MIBC. Its influence on cellular proliferation, migration, and metabolic pathways underscores its potential as a therapeutic target.